- NASDAQ:INO plummets over 15% during Thursday’s trading session.
- Shares corrected after surging over 80% last week after a presentation on its proposed COVID-19 vaccine.
- Roth Capital analyst gives severe downgrade to the stock.
NASDAQ:INO investors have been taken for quite the ride over the past two weeks with shares peaking at $18.50 while also bottoming out in the single digits. The catalyst for the recent spike was a presentation that the pharmaceutical company released for investors about the potential of its new coronavirus vaccine candidate INO-4800. While the promotional video seemed to strike the right note with investors, Wall Street analysts remained skeptical. Shares are still up over 650% over the past 52-weeks but investors have to wonder if the stock has gained as much as it will for the time being.
Roth Capital analyst Jonathan Aschoff did not mix his words when he gave a severe downgrade of $11 to Inovio’s price target and doubled down on his sell rating for the biotech firm. Aschoff affirms that INO-4800 has “virtually no chance” of winning the Operation Warp Speed race and had just as little optimism for Inovio’s HPV cancer treatment, VGX-3100, as well. After Aschoff’s downgrade, shares tumbled showing just how much power these analysts have over the price of company stocks.
INO stock news
Whether or not Aschoff’s claims are warranted it seems as though investors are buying into the analyst’s downgrade. The more damning thing about INO-4800 could be that the vaccine candidate is still in Phase 1 of its clinical trials whereas vaccine candidates from other companies like AstraZeneca (NYSE:AZN), Moderna (NASDAQ:MRNA), and Pfizer (NYSE:PFE) are all in at least Phase 3 of their respective trials. This means that the timeline for an actual vaccine may still more than a year off as rival firms bring their vaccines to market.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD: The hunt for the 0.7000 hurdle
AUD/USD quickly left behind Wednesday’s strong pullback and rose markedly past the 0.6900 barrier on Thursday, boosted by news of fresh stimulus in China as well as renewed weakness in the US Dollar.
EUR/USD refocuses its attention to 1.1200 and above
Rising appetite for the risk-associated assets, the offered stance in the Greenback and Chinese stimulus all contributed to the resurgence of the upside momentum in EUR/USD, which managed to retest the 1.1190 zone on Thursday.
Gold holding at higher ground at around $2,670
Gold breaks to new high of $2,673 on Thursday. Falling interest rates globally, intensifying geopolitical conflicts and heightened Fed easing bets are the main factors.
Bitcoin displays bullish signals amid supportive macroeconomic developments and growing institutional demand
Bitcoin (BTC) trades slightly up, around $64,000 on Thursday, following a rejection from the upper consolidation level of $64,700 the previous day. BTC’s price has been consolidating between $62,000 and $64,700 for the past week.
RBA widely expected to keep key interest rate unchanged amid persisting price pressures
The Reserve Bank of Australia is likely to continue bucking the trend adopted by major central banks of the dovish policy pivot, opting to maintain the policy for the seventh consecutive meeting on Tuesday.
Five best Forex brokers in 2024
VERIFIED Choosing the best Forex broker in 2024 requires careful consideration of certain essential factors. With the wide array of options available, it is crucial to find a broker that aligns with your trading style, experience level, and financial goals.